Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer
This trial is active, not recruiting.
|Treatment||stereotactic body radiation therapy|
|Sponsor||Roswell Park Cancer Institute|
|Start date||September 2008|
|End date||April 2020|
|Trial size||98 participants|
|Trial identifier||NCT00843726, I 124407|
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. It is not yet known which regimen of radiation therapy is more effective in treating patients with non-small cell lung cancer.
PURPOSE: This randomized phase II trial is studying the side effects of two radiation therapy regimens and to see how well they work in treating patients with stage I or stage II non-small cell lung cancer.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Intervention model||parallel assignment|
Incidence of RTOG grade 3 or higher toxicity
time frame: 1year
time frame: 5 years
Correlation between blood and serum markers and survival and toxicity
time frame: 4 years
All participants from 18 years up to 120 years old.
Inclusion Criteria: - Histologically confirmed non-small cell lung cancer - T1-T2, N0 disease measuring ≤ 5 cm( T3 tumor based on chest wall involvement is Excluded) - Surgically resectable primary disease, however patient evaluated by thoracic oncologist and deemed medically inoperable OR patient refuses surgical resection - Age >= 18 Exclusion Criteria: - Prior thoracic radiation therapy - T2 or T3 tumor greater than 5 cm or T3 tumor based on chest wall involvement - Node positive or metastatic disease - Tumor location within the zone of the proximal bronchial tree. The proximal bronchial tree is defined as the carina, right and left main bronchi, right and left upper lobe bronchi, bronchus intermedius, right middle lobe bronchus, lingular bronchus, and right and left lower lobe bronchi. The zone of the proximal bronchial tree is defined as a volume 2cm in all directions around the proximal bronchial tree. - No other conditions deemed by the PI or associates to make the patient ineligible for protocol investigations, procedures, and high-dose external beam radiotherapy (e.g., unable to lie still and breathe reproducibly) - Pregnant or unwilling to use adequate contraception
|Official title||A Phase II Randomized Study of 2 Stereotactic Body Radiation Therapy (SBRT) Regimens for Medically Inoperable Patients With Node Negative, Peripheral Non-Small Cell Lung Cancer|
|Principal investigator||Anurag K. Singh, MD|
|Description||OBJECTIVES: Primary - To compare the incidence of toxicity with two established stereotactic body radiotherapy (SBRT) regimens in patients with node-negative, peripheral stage I or II non-small cell lung cancer. Secondary - To compare quality of life, patterns of failure, disease-free survival, and overall survival of these patients after treatment with one of two established SBRT regimens. - To correlate outcomes and toxicities with imaging and patient and tumor biomarkers. OUTLINE: Patients are stratified according to Karnofsky performance status and treatment center. Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients undergo 1 high-dose fraction of stereotactic body radiotherapy (SBRT). - Arm II: Patients undergo 3 high-dose fractions (approximately 1 week apart) of SBRT. Quality of life is assessed periodically by the EORTC QLQ-C30 and -LC13 questionnaires Blood and tissue samples may be collected periodically and examined for biomarkers via ELISA and immunoblotting. After completion of study treatment, patients are followed for 5 years.|
Call for more information